Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine franchise from three to up to six approved products ...

Congenital cytomegalovirus is the most common nongenetic cause of hearing loss in childhood, yet many parents do not know ...

One-third of congenital cytomegalovirus-related hearing loss would be missed without universal screening programs.

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) through universal screening demonstrates the critical importance of early ...

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...

BofA lowered the firm’s price target on Moderna (MRNA) to $21 from $24 and keeps an Underperform rating on the shares. The firm’s 2025 revenue estimates increase by 3% due to higher-than-expected ...

November 20, 2025 | Ami Bhatt speaks with Tim Ryan about heart valve technology and the development of the Melody valve.

For cases of mild congenital heart defects, more prenatal visits are associated with lower probability of delivery at a cardiac center.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion ...